Cathy Eng, MD, ECOG-ACRIN Cancer Research Group (IMAGE)

ECOG-ACRIN Cancer Research Group

Cathy Eng, MD, ECOG-ACRIN Cancer Research Group

Caption

Dr. Cathy Eng of the Vanderbilt-Ingram Cancer Center is the lead US investigator for InterAAct, the first randomized clinical trial for inoperable anal cancer. The results of the InterAAct trial, published online by the Journal of Clinical Oncology on June 21, 2020, suggest that carboplatin-pacitaxel chemotherapy become the standard treatment for these patients.

Credit

Vanderbilt-Ingram Cancer Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.